Ionis Pharmaceuticals, Inc. or Celldex Therapeutics, Inc.: Who Invests More in Innovation?

Ionis vs. Celldex: A Decade of R&D Investment

__timestampCelldex Therapeutics, Inc.Ionis Pharmaceuticals, Inc.
Wednesday, January 1, 2014104381000241751000
Thursday, January 1, 2015100171000322292000
Friday, January 1, 2016102726000344320000
Sunday, January 1, 201796171000374644000
Monday, January 1, 201866449000414604000
Tuesday, January 1, 201942672000466000000
Wednesday, January 1, 202042534000535000000
Friday, January 1, 202153311000643000000
Saturday, January 1, 202282258000833000000
Sunday, January 1, 2023118011000899625000
Monday, January 1, 2024901530000
Loading chart...

Unlocking the unknown

Investing in Innovation: A Tale of Two Biotech Giants

In the competitive world of biotechnology, innovation is the lifeblood of success. Ionis Pharmaceuticals, Inc. and Celldex Therapeutics, Inc. have been at the forefront of this race, each investing heavily in research and development (R&D) over the past decade. From 2014 to 2023, Ionis Pharmaceuticals consistently outpaced Celldex in R&D spending, with an average annual investment nearly six times greater. In 2023, Ionis allocated approximately 900% more to R&D than Celldex, underscoring its commitment to pioneering new therapies. This trend highlights Ionis's strategic focus on innovation, which could translate into groundbreaking treatments and a competitive edge in the biotech sector. As these companies continue to push the boundaries of medical science, their R&D investments will be crucial in shaping the future of healthcare.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025